中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
上海药物研究所 [44]
采集方式
OAI收割 [44]
内容类型
期刊论文 [43]
会议论文 [1]
发表日期
2024 [1]
2023 [2]
2022 [3]
2021 [4]
2020 [2]
2019 [2]
更多
学科主题
筛选
浏览/检索结果:
共44条,第1-10条
帮助
限定条件
专题:上海药物研究所
第一署名单位
第一作者单位
通讯作者单位
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
提交时间升序
提交时间降序
发表日期升序
发表日期降序
题名升序
题名降序
作者升序
作者降序
Pharmacologically significant constituents collectively responsible for anti-sepsis action of XueBiJing, a Chinese herb-based intravenous formulation
期刊论文
OAI收割
ACTA PHARMACOLOGICA SINICA, 2024, 页码: 16
作者:
Cheng, Chen
;
Ren, Chao
;
Li, Mu-zi
;
Liu, Yi-hui
;
Yao, Ren-qi
  |  
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2024/02/27
Traditional Chinese medicine
XueBiJing
sepsis
mortality
pharmacokinetic compatibility
polypharmacology
A comprehensive analysis of the Bencao (herbal) small RNA Atlas reveals novel RNA therapeutics for treating human diseases
期刊论文
OAI收割
SCIENCE CHINA-LIFE SCIENCES, 2023, 页码: 19
作者:
Cao, Yinghao
;
Lin, Yexuan
;
Sun, Na
;
Du, Xinyi
;
Dong, Yixin
  |  
收藏
  |  
浏览/下载:22/0
  |  
提交时间:2023/10/17
small RNA
herbal decoction
cross-kingdom regulation
traditional Chinese medicine
RNA oligonucleotide drug
RNA therapeutics
Bencao small RNA Atlas
Five New Diarylbutyrolactones and Sesquilignans from Saussurea medusa and Their Inhibitory Effects on LPS-induced NO Production
期刊论文
OAI收割
PLANTA MEDICA, 2023, 页码: 11
作者:
Cao, Jing-Ya
;
Wang, Zhi-Yao
;
Stewart, Alan J. J.
;
Dong, Qi
;
Zhao, Ye
  |  
收藏
  |  
浏览/下载:18/0
  |  
提交时间:2023/04/10
Saussurea medusa
Asteraceae
diarylbutyrolactone lignan
sesquilignan
anti-inflammatory activity
molecular docking
Megastigmane sesquiterpenoids from Saussurea medusa and their anti-inflammatory activities
期刊论文
OAI收割
NATURAL PRODUCT RESEARCH, 2022, 页码: 9
作者:
Cao, Jing-Ya
;
Dong, Qi
;
Wang, Zhi-Yao
;
Zhao, Ye
;
Ren, Yu
  |  
收藏
  |  
浏览/下载:19/0
  |  
提交时间:2023/04/10
Saussurea medusa
megastigmane
sesquiterpenoid
anti-inflammatory activity
iNOS enzyme
Absorption, distribution, metabolism, and excretion of [C-14]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats
期刊论文
OAI收割
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 页码: 12
作者:
Li, Xin-mei
;
Zheng, Yuan-dong
;
Zhang, Yi-fan
;
Huan, Xia-juan
;
Yang, Chen
  |  
收藏
  |  
浏览/下载:30/0
  |  
提交时间:2022/12/13
[C-14]Mefuparib
Mefuparib (CVL218)
Blood-brain barrier
Mass balance
Tissue distribution
GastroPlus simulation
Differential early diagnosis of benign versus malignant lung cancer using systematic pathway flux analysis of peripheral blood leukocytes
期刊论文
OAI收割
SCIENTIFIC REPORTS, 2022, 卷号: 12, 期号: 1, 页码: 14
作者:
Li, Jian
;
Li, Xiaoyu
;
Li, Ming
;
Qiu, Hong
;
Saad, Christian
  |  
收藏
  |  
浏览/下载:24/0
  |  
提交时间:2022/06/15
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
期刊论文
OAI收割
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 11
作者:
Dong, Ying
;
Tang, Bi-xi
;
Wang, Qi
;
Zhou, Li-wei
  |  
收藏
  |  
浏览/下载:53/0
  |  
提交时间:2022/01/04
idiopathic pulmonary fibrosis
DDRs
kinase inhibitor
indazole derivatives
XBLJ-13
nintedanib
bleomycin-induced pulmonary fibrosismouse model
Amygdalar k-opioid receptor-dependent upregulating glutamate transporter 1 mediates depressive-like behaviors of opioid abstinence
期刊论文
OAI收割
CELL REPORTS, 2021, 卷号: 37, 期号: 5, 页码: 21
作者:
Zan, Gui-Ying
;
Wang, Yu-Jun
;
Li, Xue-Ping
;
Fang, Jun-Fan
;
Yao, Song-Yu
  |  
收藏
  |  
浏览/下载:56/0
  |  
提交时间:2021/12/16
BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer
期刊论文
OAI收割
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 卷号: 6, 期号: 1, 页码: 14
作者:
Feng, Mei
;
Wu, Zhongen
;
Zhou, Yan
;
Wei, Zhuang
;
Tian, Enming
  |  
收藏
  |  
浏览/下载:49/0
  |  
提交时间:2021/11/04
SAF-248, a novel PI3K delta-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma
期刊论文
OAI收割
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 11
作者:
Zhang, Xi
;
Duan, Yu-ting
;
Wang, Yi
;
Zhao, Xing-dong
;
Sun, Yi-ming
  |  
收藏
  |  
浏览/下载:53/0
  |  
提交时间:2021/05/24
PI3Kδ
PI3K
AKT
mTOR
diffuse large B-cell lymphoma
resistance
combination therapy